Literature DB >> 29086018

Quality of life predictors in patients with chronic inflammatory demyelinating polyradiculoneuropathy.

Ivo Bozovic1, Aleksandra Kacar1, Stojan Peric2, Ana Nikolic1, Bogdan Bjelica1, Mina Cobeljic1, Milutin Petrovic3, Aleksandar Stojanov4, Vanja Djuric5, Miroslav Stojanovic3, Gordana Djordjevic4, Vesna Martic6, Aleksandra Dominovic7, Zoran Vukojevic7, Ivana Basta1.   

Abstract

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a chronic disease which can lead to many functional impairments, and like most other chronic disorders it might significantly affect quality of life (QoL). Information about QoL in patients with CIDP from developing countries is still lacking. We, therefore, sought to complete these data mosaic by investigating QoL in patients with CIDP from Serbia and surrounding countries. Our study comprised 106 patients diagnosed with CIDP. QoL was investigated using the Serbian version of the SF-36 questionnaire. The Medical Research Council 0-5 point scale, INCAT motor and sensory scores, Krupp's Fatigue Severity Scale, and Beck Depression Inventory were also used. Factors that significantly correlated with SF-36 total score in univariate analysis were included in the multiple linear regression analysis. Physical domains of the SF-36 were more affected than mental, and the overall score was 56.6 ± 25.4. Significant predictors of worse SF-36 score in our patients with CIDP were severe fatigue (β = - 0.331, p < 0.01), higher INCAT motor score (β = - 0.301, p < 0.01), depression (β = - 0.281, p < 0.01), being unemployed/retired (β = - 0.188, p < 0.05), and shorter duration of CIDP (β = + 0.133, p < 0.01). QoL was reduced in CIDP patients, especially in physical domains. Patients with presence of fatigue and depression, with more severe motor disability, unemployed/retired ones, and those with shorter duration of the disease need special attention of clinicians since they could be at higher risk to have worse QoL.

Entities:  

Keywords:  Chronic inflammatory demyelinating polyradiculoneuropathy; Depression; Fatigue; Predictors; Quality of life; SF-36

Mesh:

Year:  2017        PMID: 29086018     DOI: 10.1007/s00415-017-8658-x

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  32 in total

1.  Pain intensity and distribution in chronic inflammatory demyelinating polyneuropathy.

Authors:  Andreas Goebel; Brian Lecky; Laura-Jane Smith; Michael Paul Lunn
Journal:  Muscle Nerve       Date:  2012-08       Impact factor: 3.217

2.  INCAT disability score: a critical analysis of its measurement properties.

Authors:  Ari Breiner; Carolina Barnett; Vera Bril
Journal:  Muscle Nerve       Date:  2014-05-17       Impact factor: 3.217

3.  Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy.

Authors:  Yaroslav Winter; Karsten Schepelmann; Annika E Spottke; Detlef Claus; Christoph Grothe; Rolf Schröder; Dieter Heuss; Stefan Vielhaber; Björn Tackenberg; Veit Mylius; Jens-Peter Reese; Reinhard Kiefer; Bertold Schrank; Wolfgang H Oertel; Richard Dodel
Journal:  J Neurol       Date:  2010-04-10       Impact factor: 4.849

4.  Functional health status of patients with chronic inflammatory neuropathies.

Authors:  Peter G Erdmann; Nico L U van Meeteren; Sandra Kalmijn; John H J Wokke; Paul J M Helders; Leonard H van den Berg
Journal:  J Peripher Nerv Syst       Date:  2005-06       Impact factor: 3.494

5.  Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group.

Authors:  I S Merkies; P I Schmitz; J P Samijn; F G van der Meché; P A van Doorn
Journal:  Neurology       Date:  1999-11-10       Impact factor: 9.910

6.  Physical training and fatigue, fitness, and quality of life in Guillain-Barré syndrome and CIDP.

Authors:  M P J Garssen; J B J Bussmann; P I M Schmitz; A Zandbergen; T G Welter; I S J Merkies; H J Stam; P A van Doorn
Journal:  Neurology       Date:  2004-12-28       Impact factor: 9.910

7.  Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial.

Authors:  T Harbo; H Andersen; A Hess; K Hansen; S H Sindrup; J Jakobsen
Journal:  Eur J Neurol       Date:  2009-02-19       Impact factor: 6.089

8.  Quality of life in patients with myotonic dystrophy type 2.

Authors:  Vidosava Rakocevic Stojanovic; Stojan Peric; Teodora Paunic; Jovan Pesovic; Milorad Vujnic; Marina Peric; Ana Nikolic; Dragana Lavrnic; Dusanka Savic Pavicevic
Journal:  J Neurol Sci       Date:  2016-04-16       Impact factor: 3.181

9.  Muscle performance relates to physical function and quality of life in long-term chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Thomas Harbo; Henning Andersen; Kristian Overgaard; Johannes Jakobsen
Journal:  J Peripher Nerv Syst       Date:  2008-09       Impact factor: 3.494

10.  Economic costs and quality of life in chronic inflammatory neuropathies in southeast England.

Authors:  M Mahdi-Rogers; P McCrone; R A C Hughes
Journal:  Eur J Neurol       Date:  2013-08-09       Impact factor: 6.089

View more
  3 in total

1.  Long-term outcome in patients with myasthenia gravis: one decade longitudinal study.

Authors:  Ivo Bozovic; Jelena Ilic Zivojinovic; Stojan Peric; Marko Kostic; Vukan Ivanovic; Dragana Lavrnic; Ivana Basta
Journal:  J Neurol       Date:  2021-09-04       Impact factor: 4.849

2.  Physical and Mental Aspects of Quality of Life in Patients With Charcot-Marie-Tooth Disease Type 1A.

Authors:  Vukan Ivanovic; Bogdan Bjelica; Aleksa Palibrk; Marija Brankovic; Ivo Bozovic; Ivana Basta; Andrija Savic; Vidosava Rakocevic Stojanovic; Aleksandra Kacar
Journal:  Front Neurol       Date:  2022-03-16       Impact factor: 4.003

3.  A longitudinal evaluation of fatigue in chronic inflammatory demyelinating polyneuropathy.

Authors:  Karissa L Gable; Stojan Peric; Michael W Lutz; Ivo Bozovic; Milutin Petrovic; Aleksandar Stojanov; Ivana Basta; Jeffrey A Allen
Journal:  Brain Behav       Date:  2022-07-21       Impact factor: 3.405

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.